Coronary Atherosclerosis: Clinical Trials

11 trials for Coronary Atherosclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown, 4 completed, 1 not yet recruiting, 1 terminated. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Unknown 5, Completed 4, Not yet recruiting 1, Terminated 1

Follow Coronary Atherosclerosis: new trials by email Literature Review of Coronary Atherosclerosis trials Research Report on Coronary Atherosclerosis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia
Phase 4Not yet recruitingChina National Center for Cardiovascular Diseases1002026-08-012026-08-13
A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
aspirin 100 mg/d, indobufen 200 mg bid - Coronary Atherosclerosis
Phase 4UnknownThe First Affiliated Hospital with Nanjing Medical University602021-10-152022-01-19
Atheroma Progression and Vulnerability Under Continuous Glucose Monitoring
continuous glucose monitoring (CGM) - Coronary Atherosclerosis
Phase 4UnknownNational Cerebral and Cardiovascular Center, Japan902019-03-012020-09-22
the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
aspirin 100mg/d therapy, aspirin 100mg/2d therapy, aspirin 100mg/3d therapy - Coronary Atherosclerosis
Phase 4UnknownThe First Affiliated Hospital with Nanjing Medical University2102017-08-202017-07-31
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
Olmesartan medoxomil tablets, Antihypertensive medication (per doctor suggestion) - Coronary Atherosclerosis
Phase 4UnknownChinese PLA General Hospital1002014-12-012015-02-11
Routine Versus Selective Use of FFR to Guide PCI
Fractional Flow Reserve (FFR) - Acute Coronary Syndrome, Coronary Atherosclerosis
Phase 4TerminatedCardiology Research UBC2612014-01-012019-02-26
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Adalimumab, Placebo - Psoriasis, Vascular Inflammation
Phase 4CompletedInnovaderm Research Inc.1072012-11-012016-09-09
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
iobitridol, gadoterate meglumine - Type 2 Diabetes Mellitus, Coronary Atherosclerosis
Phase 4CompletedGuerbet3512010-08-012019-05-31
Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis
adalimumab, UVB Phototherapy, Topical treatment - Psoriasis, Vascular Inflammation
Phase 4CompletedInnovaderm Research Inc.302009-07-012011-10-28
Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)
Calcium channel blockers (amlodipine, azelnidipine) - Hypertension, Coronary Atherosclerosis
Phase 4CompletedJuntendo University1992005-12-012021-05-14
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
pioglitazone - Coronary Atherosclerosis, Inflammation
Phase 4UnknownNational Taiwan University Hospital1202004-11-012006-02-27

Narrower conditions

Coronary Artery Disease (11)  ·  Diabetes Mellitus, Type 2 (2)  ·  Plaque, Amyloid (2)  ·  Psoriasis (2)  ·  Acute Coronary Syndrome (1)  ·  Angina, Unstable (1)  ·  Atherosclerosis (1)  ·  Calcinosis (1)  ·  Coronary Disease (1)  ·  Hyperlipidemias (1)  ·  Hypertension (1)  ·  Hypertriglyceridemia (1)  ·  Inflammation (1)  ·  Insulin Resistance (1)

Broader conditions

Arterial Occlusive Diseases (11)  ·  Arteriosclerosis (11)  ·  Cardiovascular Diseases (11)  ·  Heart Diseases (11)  ·  Myocardial Ischemia (11)  ·  Vascular Diseases (11)  ·  Coronary Disease (10)  ·  Metabolic Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Glucose Metabolism Disorders (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Diabetes Mellitus (2)  ·  Endocrine System Diseases (2)  ·  Pathological Conditions, Anatomical (2)  ·  Skin Diseases (2)

Interventions

Adalimumab (2)  ·  Aspirin (2)  ·  Therapeutics (2)  ·  indobufen (2)  ·  Amlodipine (1)  ·  BID protein, human (1)  ·  Calcium Channel Blockers (1)  ·  Continuous Glucose Monitoring (1)  ·  Olmesartan Medoxomil (1)  ·  Pioglitazone (1)  ·  azelnidipine (1)  ·  eicosapentaenoic acid ethyl ester (1)  ·  gadoterate meglumine (1)  ·  iobitridol (1)

Sponsors

Innovaderm Research Inc. (2)  ·  The First Affiliated Hospital with Nanjing Medical University (2)  ·  Cardiology Research UBC (1)  ·  China National Center for Cardiovascular Diseases (1)  ·  Chinese PLA General Hospital (1)  ·  Guerbet (1)  ·  Juntendo University (1)  ·  National Cerebral and Cardiovascular Center, Japan (1)  ·  National Taiwan University Hospital (1)

Countries

China (4)  ·  Canada (3)  ·  Japan (2)  ·  South Korea (1)  ·  Taiwan (1)

Top investigators

Robert Bissonnette, MD (2)  ·  Anthony Fung, MBBS, FRCPC (1)  ·  Chen Yundai (1)  ·  Jean-Claude Tardif, MD (1)  ·  Jean-Claude Tardif, MD, FRCPC (1)  ·  Tzung-Dau Wang, MD, PhD (1)  ·  Yu Kataoka, MD (1)

Results publications

PMID 21471671, PMID 23204039, PMID 23214115, PMID 26739013, PMID 28286061, PMID 31737515